title: Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
abstract: BACKGROUND
  In this report we describe the in vivo antibacterial activity of linezolid in an experimental graft infection model in rats and compare it with teicoplanin. The objective of this study was also to determine the effects of the interaction of linezolid when it was combined with rifampicin and test this effect against strains of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
  
  
  METHODS
  Graft infections were established in the subcutaneous tissue of 130 Wistar rats by implantation of Dacron grafts followed by a topical inoculation with 2 x 10(7) CFU of clinical isolates of MRSA and MRSE. The study included a control group and six groups for each of the staphylococcal strains: an inoculated group that did not receive any antibiotic prophylaxis, two inoculated groups that received intraperitoneal prophylaxis with teicoplanin or linezolid alone, an inoculated group that received rifampicin-soaked grafts, and two inoculated groups that received a combination prophylaxis consisting of intraperitoneal teicoplanin or linezolid and rifampicin-soaked grafts.
  
  
  RESULTS
  There was a reduction in the quantitative bacterial graft cultures in all prophylaxis groups when compared with inoculated control groups. There was not a statistically significant difference between linezolid and teicoplanin prophylaxis groups. The best results were obtained by a combination of rifampicin-soaked grafts with linezolid or teicoplanin.
  
  
  CONCLUSIONS
  We found no evidence to suggest that linezolid differs from teicoplanin regarding effectiveness in the prevention of prosthetic vascular graft infection. Linezolid plus rifampicin and teicoplanin plus rifampicin are demonstrated to be valuable prophylactic regimens.
authors.affiliation: Department of Cardiovascular Surgery, School of Medicine, Pamukkale University, Denizli, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Sacar
authors.forename: Suzan
authors.initials: S
authors.lastname: Sacar
authors.forename: Ilknur
authors.initials: I
authors.lastname: Kaleli
authors.forename: Gokhan
authors.initials: G
authors.lastname: Onem
authors.forename: Huseyin
authors.initials: H
authors.lastname: Turgut
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Goksin
authors.forename: Vefa
authors.initials: V
authors.lastname: Ozcan
authors.forename: Bilal
authors.initials: B
authors.lastname: Kaan Inan
authors.forename: Harun
authors.initials: H
authors.lastname: Duver
authors.forename: Ahmet
authors.initials: A
authors.lastname: Baltalarli
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001807:Blood Vessel Prosthesis; D004357:Drug Synergism; D000069349:Linezolid; D008297:Male; D016106:Methicillin Resistance; D023303:Oxazolidinones / Q000494:pharmacology*; D016459:Prosthesis-Related Infections / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D012293:Rifampin / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000502:physiology; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000502:physiology; D017334:Teicoplanin / Q000494:pharmacology
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D017334:Teicoplanin; D000069349:Linezolid; D012293:Rifampin